Spots Global Cancer Trial Database for TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma
Official Title: TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma
Study ID: NCT04490694
Conditions
Study Description
Brief Summary: It is an exploratory clinical study aimed to evaluate the efficacy and safety of TACE combined with Lenvatinib in the treatment of patients with BCLC stage B and C HCC.Treatment will continue until the death or intolerable toxicity or patients withdrawal of consent,and the target sample size is 54 individuals.
Detailed Description: This is a prospective, single-center and single-arm exploratory clinical study designed to evaluate the efficacy and safety of TACE combined with Lenvatinib in the treatment of patients with BCLC stage B and C hepatocellular carcinoma.Treatment will continue until the death or intolerable toxicity or patients withdrawal of consent,and the target sample size is 54 individuals.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Department of Interventional Radiology, Zhongshan Hospital, Fudan University., Shanghai, Shanghai, China
Contact Details
Name: Zhiping Yan, M.D.
Affiliation: Fudan University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
